TY - JOUR
T1 - Adaptable framework for cost-analyses in radiotherapy
T2 - Application to the cost of proton versus photon therapy for lung cancer in The Netherlands
AU - Sugden, Bradley M
AU - Witlox, Willem J A
AU - Ramaekers, Bram L T
AU - Hattu, Djoya
AU - Vluggen, Boy
AU - van Loon, Judith
AU - Jacobs, Maria
AU - Joore, Manuela A
AU - De Ruysscher, Dirk K M
N1 - Copyright © 2025 The Authors. Published by Elsevier B.V. All rights reserved.
PY - 2025/5
Y1 - 2025/5
N2 - BACKGROUND/PURPOSE: Proton radiation-therapy (PrT) may provide clinical benefit for lung cancer compared to photon radiation-therapy (PhT), however is more costly. Literature reporting costs for PrT, PhT, and comparisons thereof, particularly from a societal perspective, are scarce. This study aims to provide an adaptable framework to estimate PrT/PhT costs, demonstrated through application to lung cancer, from societal and healthcare perspectives.METHODS: Dutch Costing Guidelines were followed to estimate costs from first referral to end of treatment. A parallel base-case was conducted whereby centre-specific inputs replaced general input parameters. Costs were calculated probabilistically using Monte Carlo simulations (10,000 iterations) and separated into three categories: healthcare (subdivided: personnel, non-personnel), patient/family, and costs in other sectors. Direct healthcare personnel costs were estimated using time-driven activity-based costing, allowing separation of non-fraction-dependant costs. Further sensitivity/scenario analyses were explored.RESULTS: Fixed costs (guideline[centre-specific] analyses mean) from a societal perspective were €11,208[€12,299] for PrT and €9,651[€10,977] for PhT. Variable costs per fraction were €932[€798] for PrT and €265[€265] for PhT. Total cost ratio for PrT to PhT was 2.00[1.74] for 20 fraction schedules and 2.23[1.91] for 30 fractions. The greatest incremental cost driver category for PrT versus PhT was non-(direct)personnel healthcare costs (overheads, capital outlays).CONCLUSION: An adaptable framework for probabilistic cost-analyses was developed. Results highlight cost disparities between PrT and PhT and serves to inform future cost-effectiveness analyses. Scenarios reveal potential for clinical experience and increased capacity to narrow differences. Parallel base-case analyses highlight cost disparities arising when utilising generic vs centre-specific inputs, and potential outcome differences between centres.
AB - BACKGROUND/PURPOSE: Proton radiation-therapy (PrT) may provide clinical benefit for lung cancer compared to photon radiation-therapy (PhT), however is more costly. Literature reporting costs for PrT, PhT, and comparisons thereof, particularly from a societal perspective, are scarce. This study aims to provide an adaptable framework to estimate PrT/PhT costs, demonstrated through application to lung cancer, from societal and healthcare perspectives.METHODS: Dutch Costing Guidelines were followed to estimate costs from first referral to end of treatment. A parallel base-case was conducted whereby centre-specific inputs replaced general input parameters. Costs were calculated probabilistically using Monte Carlo simulations (10,000 iterations) and separated into three categories: healthcare (subdivided: personnel, non-personnel), patient/family, and costs in other sectors. Direct healthcare personnel costs were estimated using time-driven activity-based costing, allowing separation of non-fraction-dependant costs. Further sensitivity/scenario analyses were explored.RESULTS: Fixed costs (guideline[centre-specific] analyses mean) from a societal perspective were €11,208[€12,299] for PrT and €9,651[€10,977] for PhT. Variable costs per fraction were €932[€798] for PrT and €265[€265] for PhT. Total cost ratio for PrT to PhT was 2.00[1.74] for 20 fraction schedules and 2.23[1.91] for 30 fractions. The greatest incremental cost driver category for PrT versus PhT was non-(direct)personnel healthcare costs (overheads, capital outlays).CONCLUSION: An adaptable framework for probabilistic cost-analyses was developed. Results highlight cost disparities between PrT and PhT and serves to inform future cost-effectiveness analyses. Scenarios reveal potential for clinical experience and increased capacity to narrow differences. Parallel base-case analyses highlight cost disparities arising when utilising generic vs centre-specific inputs, and potential outcome differences between centres.
KW - Adaptable
KW - Cost-Analysis
KW - Framework
KW - Lung cancer
KW - Photon
KW - Proton
KW - Societal perspective
U2 - 10.1016/j.radonc.2025.110832
DO - 10.1016/j.radonc.2025.110832
M3 - Article
C2 - 40058706
SN - 0167-8140
VL - 206
JO - Radiotherapy and Oncology
JF - Radiotherapy and Oncology
M1 - 110832
ER -